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a  b  s  t  r  a  c  t
Endothelial  Progenitor  Cells  (EPCs)  are  bone  marrow  derived  cells  able  to differentiate  in  mature  endothe-
lial cells  (EC)  contributing  to the  generation  of  new  vessels,  connecting  to ﬁbronectin,  and  forming
colonies  and/or  colony  forming  units.
Since circulating  EPCs  can  be  actively  considered  part  of  endothelial  damage  in several  cardiovascular
diseases  and  autoimmune  disorders  the  possibility  to  have  a  measure  for endothelium  damage  shouldeywords:
PCs
heumatoid arthritis
ES
asculitis
be  considered  of  interest  to predict  the  patient  out-come.  At  the  same  time  the  EPCs  proliferative  and
regenerative  role  could  be considered  for therapeutic  applications.
Studies  have  been  performed  to elucidate  the  role  of  EPCs  in  Systemic  Sclerosis  and  many  review  and
articles  published  on this  topic.
In the  present  paper  we  aimed  to  review  the role of  EPCs  in  other  autoimmune  disorders.
© 2016  Published  by Elsevier  Ireland  Ltd.. Introduction
Endothelial Progenitor Cells (EPCs) are bone marrow derived
ells able to differentiate in mature endothelial cells (EC) contribut-
ng to the generation of new vessels, connecting to ﬁbronectin, and
orming colonies and/or colony forming units (Asahara, 1997). The
henotypical marker of EPCs is CD133 that is absent on mature
ndothelial cells. Other surface markers were identiﬁed on EPCs,
D34+/VEGFR2+/CD146+ (Rauscher et al., 2003). However, to date
here are no standardized methods to quantify and identify EPCs
nd the protocols used vary between studies (Kuwana and Okazaki,
012). In particular, studies on quantiﬁcation of circulating EPCs
umber in various autoimmune diseases are controversial proba-
ly because of different microeviroment, drugs, cytokine and other
actors modifying their survival (Cipriani et al., 2011; Kuwana et al.,
004; Del Papa et al., 2004; Paleolog et al., 2005; Moonen et al.,
007).
∗ Corresponding author.
E-mail address: Giuliana.guggino@unipa.it (G. Guggino).
1 The ﬁrst two  authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.mad.2016.05.001
047-6374/© 2016 Published by Elsevier Ireland Ltd.The number of circulating EPCs depends on integrity of ves-
sel wall and on their capability to migrate (Cipriani et al., 2011;
Hill, 2003). These cells show high proliferation capability and are
referred as “true or classical” EPC (Cipriani et al., 2011; Hristov and
Weber, 2008). More recently, studies have also described another
subset of EPCs (named monocytic derived EPCs) with lower abil-
ity to create new vessels in vivo than “classical” EPCs (Urbich and
Dimmeler, 2004). Monocytic derived EPCs were found increased in
several autoimmune disorders showing paradoxically, enhanced
angiogenetic but reduced vasculogenetic properties [Yamaguchi
et al., 2010]. Monocytic EPCs are oligopotent cells able to differenti-
ate not only into endothelial cells but also in pericytes and smooth
muscle cells [Yamaguchi et al., 2010].
Abnormalities in circulating EPC levels and function have been
observed in a large number of studies on different cardiovascular
diseases (CVDs). As result, EPCs have been suggested as diagnos-
tic and prognostic CVD biomarkers (as extensively summarized
in Balistreri et al., 2015). Cotemporally, a signiﬁcant correlation
between in vitro EPC senescence and CVD risk proﬁle has been also
reported in donors (as extensively summarized in Balistreri et al.,
2015). Thus, EPCs might be considered as an optimal predictive
biomarker for vascular function and cardiovascular risk. Actually,
it is also emerging that the number of circulating EPC cells studies
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ight also be used as an optimal measure for endothelium dam-
ge, and consequently it should be considered of interest to predict
he patient out-come. At the same time the EPCs proliferative and
egenerative role could be considered for therapeutic applications,
s demonstrated in several studies in animal models and clinical
uman trials (as reviewed in Balistreri et al., 2015).
These relevant features of circulating EPC cells in CVDs and the
linical applications which might derived from them, have also led
o elucidate the role of EPCs in some autoimmune diseases, such as
ystemic Sclerosis. Many review and articles have been published
n this topic (Kahlenberg, 2011; Yamaguchi et al., 2010; Hill, 2003;
anetti, 2010; Blaise et al., 2014; Andrigueti et al., 2015). Here, we
imed to review the role of EPCs in rheumatic autoimmune dis-
ases (ARDs), including systemic lupus erythematosus, vasculitis
nd rheumatoid arthritis.
. ARDs and high prevalence of CVDs
Patients affected by ARDs show a signiﬁcant increased risk
or developing CVDs. The risk is approximately 1.4 fold higher in
atients with Rheumatoid Arthritis (RA) (Watson et al., 2003) and
p to 5–6 fold higher in patients with Systemic Lupus Erythemato-
us (SLE) (Manzi et al., 1997). This risk is exaggerated in younger
LE patients and may  be up to 52 fold greater in those aged 35–44
ears. The onset of premature CVDs in RA and SLE patients is related
o a co-presence of traditional risk factors (i.e. hypertension, dia-
etes mellitus and dyslipidaemia) and disease- speciﬁc factors (i.e.
orticosteroid use and proinﬂammatory cytokines) (Esdaile et al.,
001; Bruce et al., 2003; Bruce, 2005; Lee et al., 2006). Furthermore,
atients with ARDs might develop subclinical CVDs, which are
lso increased in patients with RA and SLE. Carotid artery plaque,
arotid intima-medial thickness (IMT) and coronary calciﬁcation
re more prevalent in both RA and SLE (Ferrante, 2009; Kumeda,
002; Asanuma, 2003; Roman et al., 2003; Roman et al., 2006;
hmad et al., 2007; Wang et al., 2009).
As above mentioned, CVDs in ARDs seem to be caused
y traditional and non- traditional risk factors. Besides other
actors, inﬂammation and immunologic abnormalities, the quan-
ity and quality of lipoproteins, hypertension, insulin resis-
ance/hyperglycemia, obesity and underweight, presence of
latelets bearing complement protein C4d, reduced number and
unction of endothelial progenitor cells, apoptosis of endothelial
ells, epigenetic mechanisms, renal disease, periodontal disease,
epression, hyperuricemia, hypothyroidism, sleep apnea and vita-
in  D deﬁciency may  contribute to the premature CVD. Although
ost research has focused on systemic inﬂammation, vascular
nﬂammation may  play a crucial role in the premature CVD in
RDs. It may  be involved in the development and destabilization
f both atherosclerotic lesions and of aortic aneurysms (a known
omplication of ARDs). Inﬂammation in subintimal vascular and
erivascular layers appears to frequently occur in CVD, with a
igher frequency in ARD than in non-ARD patients. It is possible
hat this inﬂammation is caused by infections and/or autoimmu-
ity, which might have consequences for treatment. Importantly,
rugs targeting immunologic factors participating in the subintimal
nﬂammation (e.g., T- and B-cells) might have a protective effect
n CVD. Interestingly, vasa vasorum and cardiovascular adipose
issue may  play an important role in atherogenesis. Inﬂamma-
ion and complement depositions in the vessel wall are likely
o contribute to vascular stiffness. Based on biopsy ﬁndings, also
nﬂammation in the myocardium and small vessels may  contribute
o premature CVD in ARDs (cardiac ischemia and heart failure)
Castellon and Bogdanova, 2016) There is an enormous need for an
mproved CVD prevention in ARDs. Studies examining the effect ofnd Development 159 (2016) 44–48 45
DMARDs/biologics on vascular inﬂammation and CV risk are war-
ranted.
3. Endothelium dysfunction in ARD patients
It is well known that endothelial dysfunction represents the
early stage of the development of CVD. In RA, endothelial dys-
function occurs early in the disease course and is associated with
systemic inﬂammation (Vaudo et al., 2004; Kerekes et al., 2008;
Hannawi et al., 2009). The pathophysiological mechanisms which
result in endothelial dysfunction in these patients are, however,
unknown, although associations have been found between abnor-
mal  ﬂow medial dilation and low-density lipoprotein (Vaudo et al.,
2004), rheumatoid factor (Marder et al., 2011), anticyclic
citrullinated peptide (APCA) antibodies (Hjeltnes et al., 2011)
and interferon-gamma (Kerekes et al., 2008) in RA. In patients
with SLE, FMD  has been associated with elevated interferon-alpha
(Somers et al., 2012), lupus disease activity, and altered serum plas-
minogen activator inhibitor-1 (PA-1) (Somers et al., 2005).
4. An imbalance between endothelial damage and repair: a
possible cause of high prevalence of CVDs in ARD patients
The endothelium, in common with other tissues, is in a con-
stant state of wear and repair. In the post-embryonic state, new
vessels were thought to develop only from the proliferation of
mature endothelial cells. This process is termed angiogenesis and
is important in tissue repair following physical injury or ischaemia.
In aged individuals, or in patients affected by chronic inﬂamma-
tory diseases, such as ARDs, an imbalance between EC damage and
impaired EC repair has been suggested as proposed initial step in
the development of atherosclerosis, or of other pathological age-
related vascular conditions, i.e. medial degeneration and vascular
remodeling associated with other CVDs. Early detection of cel-
lular and molecular mechanisms related to such imbalance with
potential therapeutic interventions, may  reduce atherogenesis and
subsequent cardiovascular events, and onset and progression of
medial degeneration and vascular remodeling related of other age-
related CVDs (Williamson et al., 2012; Felice et al., 2013; Olivieri
et al., 2013). Endogenous regeneration of the vessel wall involves
a large panel of cells, such as EPCs and mature EC cells, which are
capable to restore the endothelium in a concerted interaction. Thus,
it is important to understand the cellular and molecular mecha-
nisms of EPCs and their role in ARDs.
In the next paragraphs, we  tried to give a contribution describing
the role of EPC in SLE, vasculitis and RA.
4.1. EPC in SLE
Evidence from epidemiological studies demonstrates that SLE is
associated with an increased risk of premature cardiovascular com-
plications due to accelerated atherosclerosis, which signiﬁcantly
contributes to morbidity and mortality in these patients. Different
studies suggest that traditional risk factors may play a role but do
not fully explain the increased prevalence of atherosclerosis (Petri
et al., 1992; Rahman et al., 1999; Esdaile et al., 2001; Rajagopalan
et al., 2004). In addition the so-called non-traditional factors, such
as systemic chronic inﬂammation, the presence of autoantibodies
and the use of immunosuppressive drugs, have been suggested to
have a role (Asanuma, 2003; Schoenfeld, 2013).
It has been previously reported that SLE is characterized by
accelerated endothelial cell (EC) apoptosis, which correlates with
reduced endothelial function, and that circulating EC can be used
as a marker of vessel damage (Asahara, 1997). A crucial aspect to
preserve endothelial integrity is to maintain the balance between
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ndothelial damage and repair. Vascular repair appears to be medi-
ted by the recruitment of bone marrow–derived EPCs to the
ite of endothelial injury (Peichev et al., 2000). The EPCs are a
eterogeneous population that contribute to the restoration of
ndothelial function because of their ability to differentiate into
ature ECs once incorporated into circulating blood (Deng et al.,
010). Although modulation of EPC numbers has been identiﬁed
n the course of cardiovascular disease or vascular trauma (which
ppears to be predictive of clinical coronary events in the gen-
ral population), there is still much controversy regarding their
rue identity and role. In SLE, while most of the studies demon-
trated low percentages of circulating EPC (Lee et al., 2007; Moonen
t al., 2007; Westerweel et al., 2007; Robak et al., 2009), results
re inconsistent, most likely due to different protocols adopted
or identifying EPC (Hooks et al., 1979). Nevertheless, whether the
umber of circulating EPC can predict cardiovascular events in
atients with SLE remains to be answered by prospective studies.
ro-angiogenic factors, such as VEGF can mobilize EPCs and may
otentiate their recruitment to the site of vascular injury (Asahara
t al., 1999; Raﬁi et al., 2002). Several cytokines are involved in
PC mobilization, survival, recruitment or function (Mao, 2012;
usilli, 2015; Rodríguez-Carrio, 2012). Besides the formation of
utoantibodies, one of the most prominent features in patients with
LE is the continuous activation of the type I interferon (IFN) sys-
em (Tsokos, 2011; Ronnblom et al., 2011; Cederblad et al., 1998).
ncreased levels of type I IFN in SLE sera were reported already
ore than 30 years ago, and with the techniques of genome-wide
xpression analysis, it was later shown that the majority of patients
ith SLE have an activated type I IFN system, as judged by the
ncreased expression of type I IFN-induced genes (a type I IFN sig-
ature) (Chiche, 2014). The over activated type I IFN system in SLE
an be, at least partly, explained by the presence of endogenous
nterferon inducers in such patients, which triggers the plasma-
ytoid dendritic cells (pDCs) to type I IFN production (Vallin et al.,
999; Rajagopalan et al., 2004). Several investigators have proposed
hat type I interferons (IFNs) play an important role in the patho-
enesis of accelerated atherosclerosis in patients with adult-onset
LE (Denny et al., 2007; Bennett et al., 2003; Werner et al., 2005),
hrough deleterious pleiotropic effects on the vasculature. Type I
FNs induce signiﬁcant impairment of the capacity of EPCs to dif-
erentiate into mature endothelial cells and repair the vasculature
Denny et al., 2007; Thacker et al., 2012). In murine models of lupus
nd atherosclerosis, type I IFN blocking agents abrogates endothe-
ial dysfunction, the prothrombotic phenotype, plaque formation,
nd abnormal vasculogenesis (Thacker et al., 2010; Mohan et al.,
015; Kahlenberg, 2011). In addition type I IFNs repress expres-
ion of the pro-angiogenic cytokine IL- 1 (41). Importantly, type I
FNs have also been shown to upregulate NLRP3, caspase-1 and IL-
8 in human EPC cultures, which results in enhanced production
f IL-18. IL-18, in turn, has inhibitory effects on EPC differentia-
ion to mature endothelial cells (Kahlenberg, 2014). Inhibition of
aspase-1 in these cultures prevents the detrimental effects of type
 IFNs (Kahlenberg, 2014), and absence of functional caspase-1 also
enders murine bone marrow EPC cultures resistant to the detri-
ental effects of pristane-induced lupus and improves endothelial
unction in vivo (Cates et al., 2015). Finally it was shown that the
egative effect of IFN on the function and differentiation of EPCs
ould be enhanced by the action of IL-10, a cytokine involved in the
athogenesis of SLE by promoting the production of high titer of
utoantibodies via B cell activation (Jennette et al., 2013).
.2. EPCs in vasculitisSystemic vasculitis is characterised by systemic inﬂammation,
ndothelial activation, and (in some cases) necrosis of blood ves-
el walls leading to multiorgan injury (Hoffman and Calabrese,nd Development 159 (2016) 44–48
2014, Savage, 2009). Endothelial activation and injury are central
to the pathogenesis of vasculitides with increased endothelial cell
adhesion molecule expression, and a switch to a prothrombotic
endothelial phenotype, both contributing to the vascular pathol-
ogy (Tomasson et al., 2009; Blake et al., 1985). In systemic vasculitis
impaired endothelial repair capacity of EPC was addressed and the
signiﬁcant inﬂammatory milieu could adversely affect EPC func-
tion, resulting in defective colony formation, adhesion and ability
to integrate into vascular networks. Although it has been recog-
nized for many years that endothelial damage is central to the
pathogenesis of vasculitis surprisingly little is known about the bal-
ance between endothelial injury and repair (Brogan et al., 2004;
Woywodt et al., 2003; Nakatani et al., 2003).
de Groot et al. (2007) have studied the role of EPCs in ANCA-
associated vasculitis. They have found not different percentage
of EPCs between patients with active disease and controls, con-
versely EPCs count was increased in patients with disease remission
respect to controls (Závada et al., 2009). Thus, EPCs could be con-
sidered as a marker of vascular regeneration inversely correlate
with disease activity. In this regards EPCs could be involved in the
repair of vascular defects in patients with ANCA associated vas-
culitis (AAV). A similar time course for EPCs has been reported
in patients with Kawasaki disease where the number of EPCs was
increased during the subacute phase and decreased during active
phase or remission (de Groot et al., 2007).
In contrast, however recent studies showed signiﬁcant reduced
levels of numbers of EPC-CFU during the active phase of the disease
and suggested that impairment of EPC function was  mediated in
part by inﬂammatory circulating endothelial cells (Holmén et al.,
2005).
4.3. EPCs in RA
Rheumatoid Arthritis (RA) is an autoimmune systemic disease
characterized by cardiovascular comorbidity (del Rincon et al.,
2007), mostly due to its inﬂammatory nature which contributes
to an accelerated development of atherosclerosis (del Rincon et al.,
2007; Libby et al., 2002). Atherosclerotic plaque and sinovia from
RA patients share same features, including a typical inﬂamma-
tory microenvironment composed by inﬁltrating leucocytes (Full
et al., 2009), cytokines, adhesion molecules and an activated
endothelial phenotype. The loss of protective antioxidant and
anti-inﬂammatory mechanisms seems to be responsible for the
endothelial dysfunction which is the earliest, but yet reversibile,
stage of atherosclerotic plaque formation (Deanﬁeldet et al., 2007).
Supporting this hypothesis, endothelial dysfunction has been found
also in young RA patients without traditional cardiovascular risk
factors (Hansel et al., 2003), thus suggesting the involvement of
disease-related mechanisms.
Physiologically, vasculogenesis, the de novo formation of blood
vessels from mesoderm, is driven by the recruitment of undiffer-
entiated mesodermal cells to the endothelial lineage, or EPCs, and
has a key role in embryo and adult tissue development, in vascu-
lar repair and also in atherosclerosis (Paleolog et al., 2005; Peichev
et al., 2000; Asahara, 1997; Jodon de Villeroché et al., 2010; Pakozdi
et al., 2009).
During vasculogenesis, EPCs, recruited from the bone mar-
row, differentiate in situ into mature endothelial cells under the
inﬂuence of nitric oxide (NO) produced by the activation of the
endothelial NO synthase (eNOS) (Aicher et al., 2003). Vasculogen-
esis require a tightly regulated activation of several growth factors
and their receptors. Recruitment of EPCs to the site of endothelial
injury is induced and potentiated by VEGF as well as by several pro-
inﬂammatory and immunosupressor cytokines, such as IL-1, IL-6,
IL-8, IL-17A, TGF-, GM-CSF and IFN- (Rodríguez-Carrio, 2012).
Recently, it has been reported that VEGFR-1-induced proliferation
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f bone marrow hematopoietic cells promotes chronic inﬂamma-
ion in a rheumatoid arthritis murine model (Aicher et al., 2003),
hus conﬁrming that inhibiting VEGFR-1 activity might be thera-
eutically beneﬁcial for RA patients.
An inverse correlation between EPCs number and the Fram-
ngham risk score (Hill, 2003) in both long-standing (Gonzalez-
uanatey et al., 2003) and early RA patients have been documented
Bergholm et al., 2002). On the other hand have been also described
ncreased numbers of late-outgrowth EPCs in RA, on owing an
ncreased colony formation capacity. Indeed two EPCs subpop-
lations, called monocytic and hemangioblastic EPCs have been
ecently identiﬁed as early- outgrowth and late-outgrowth EPCs,
espectively (Hristov and Weber, 2008).
Finally corticosteroids and tumor necrosis factor-alpha (TNF-)
lockers were described to stimulate EPCs number and function
nd to restore defective vasculogenesis (Grisar et al., 2007; Ablin
t al., 2006). Further details, however, on the effects of these agents,
peciﬁcally on the function of late-outgrowth EPCs in long-term
ontrolled studies, are needed, in order to evaluate the effect of
his class of drugs on atherosclerotic process progression.
. Conclusions
In describing the role of EPCs in ARDs, we evidenced their
ltered number and function and additionally underlined that
heir modulation in vivo seem to restore rejuvenation and to
mprove cardiovascular outcomes. In order to achieve very efﬁ-
ient therapeutic applications experimental studies in humans and
on-human models and ex vivo functional analysis would be per-
ormed. Furthermore, a deeper understanding of how monocytic
erived EPCs and EPCs facilitate endothelial repair would lead to
he identiﬁcation of novel therapeutic targets across a range of
atient groups, who develop early or accelerated CVDs. Speciﬁcally
n patients with ARDs, and particularly in RA and SLE, it remains
o be determined whether simply controlling inﬂammation will
e sufﬁcient to restore EPC or monocyte EPCs function. In sum-
ary, preventing premature CVD remains an important challenge
n the management of patients with ARDs, and particularly with RA
nd SLE; where newer agents for controlling disease activity with
reater efﬁcacy, are investigated
There are no targeted therapies to reduce CVD in these patients
nd well established treatments in the general population (e.g.
tatins) have not yet conclusively shown beneﬁt in RA or SLE.
here is great potential to utilise the homeostatic endothelial repair
echanisms to prevent the development of endothelial dysfunc-
ion, at a time point long before the development of clinical disease
r even appearance of atherosclerotic plaque. In order to develop
nd implement these novel approaches, it is imperative to study the
unction and role of these cells in more detail both in ARD patients
nd in health in order to develop targeted therapies to reverse the
lear abnormalities in ECP function in ARDs.
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